Skip to content
OpenCapital
Get started

CareDx CDNA Marketable Securities, Amortized Cost, Short Term

Other financials

Income statement

See full
Revenue$117.7M+39.0%
Operating income$1.2M+109%
Net income$2.8M+127%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$78.5M-12.1%
Total debt$24.5M-19.1%
Total equity$313.5M-17.3%
Total assets$411.1M-16.0%

Cash flow

See full
Operating cash flow$4.3M+116%
CapEx$3.8M+134%
Free cash flow$514.0K+102%

Valuation

See full
Market cap$1.4B+32.2%
Enterprise value$1.35B+34.6%
P/S3.4×+0.3×

Profitability

See full
Gross margin65.5%—
Operating margin-3.9%-18.3pp
Net margin-2%-19.9pp
FCF margin-0%0.0pp

Returns & leverage

See full
Return on equity-2.4%-21.9pp
Debt / equity0.1×0.0×
Current ratio3.4×-0.7×

Where this comes from

Reported directly by CareDx in its filing.

Tagged under the XBRL concept cdna:MarketableSecuritiesAmortizedCostShortTerm.

The official record: CareDx’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about CareDx's marketable securities, amortized cost, short term.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CareDx's marketable securities, amortized cost, short term?
CareDx (CDNA) reported marketable securities, amortized cost, short term of $120.15M in Q1 2026.
How has CareDx's marketable securities, amortized cost, short term changed year-over-year?
CareDx's marketable securities, amortized cost, short term decreased by 15.5% year-over-year, from $142.17M to $120.15M.
What is the long-term trend for CareDx's marketable securities, amortized cost, short term?
Over 3 years (2022 to 2025), CareDx's marketable securities, amortized cost, short term has grown at a -12.5% compound annual growth rate (CAGR), from $203.17M to $135.94M.